CD274 and non-small cell lung carcinoma: For example, the expression of PD-L1 in circulating endothelial cells from patients with non-small cell lung cancer undergoing immunotherapy has been associated with poor outcomes [56], thus highlighting the idea of a potential combined anti-angiogenic agent and immunotherapy prescription for these individuals.